Asian Journal of Pharmaceutical Sciences (Oct 2014)

Nanotechnology and vaccine development

  • Mi-Gyeong Kim,
  • Joo Yeon Park,
  • Yuna Shon,
  • Gunwoo Kim,
  • Gayong Shim,
  • Yu-Kyoung Oh

DOI
https://doi.org/10.1016/j.ajps.2014.06.002
Journal volume & issue
Vol. 9, no. 5
pp. 227 – 235

Abstract

Read online

Despite the progress of conventional vaccines, improvements are clearly required due to concerns about the weak immunogenicity of these vaccines, intrinsic instability in vivo, toxicity, and the need for multiple administrations. To overcome such problems, nanotechnology platforms have recently been incorporated into vaccine development. Nanocarrier-based delivery systems offer an opportunity to enhance the humoral and cellular immune responses. This advantage is attributable to the nanoscale particle size, which facilitates uptake by phagocytic cells, the gut-associated lymphoid tissue, and the mucosa-associated lymphoid tissue, leading to efficient antigen recognition and presentation. Modifying the surfaces of nanocarriers with a variety of targeting moieties permits the delivery of antigens to specific cell surface receptors, thereby stimulating specific and selective immune responses. In this review, we introduce recent advances in nanocarrier-based vaccine delivery systems, with a focus on the types of carriers, including liposomes, emulsions, polymer-based particles, and carbon-based nanomaterials. We describe the remaining challenges and possible breakthroughs, including the development of needle-free nanotechnologies and a fundamental understanding of the in vivo behavior and stability of the nanocarriers in nanotechnology-based delivery systems.

Keywords